AI-Based Model for Predicting Type 2 Diabetes Risk Using Lifestyle Factors Among Senior Nursing Students (AI-T2DM-NS)

October 30, 2026 updated by: Mohamed Fakhry Ahmed Salem, Alexandria University

Developing an Artificial Intelligence-Based Model for Predicting Type 2 Diabetes Risk Using Lifestyle Factors Among Senior Nursing Students at Alexandria University

This study will develop and test an artificial intelligence (AI) model that estimates the risk of type 2 diabetes among senior (third- and fourth-year) nursing students at the Faculty of Nursing, Alexandria University, Egypt. Type 2 diabetes is common in Egypt, and many cases are not diagnosed. Daily habits such as diet, physical activity, and body weight play a major role in who develops it. Nursing students will become health care providers who teach patients about healthy living, so it is important to find those who may be at risk early.

About 200 students will take part. Each student will complete a questionnaire about personal information and the Health-Promoting Lifestyle Profile II, which measures health habits such as nutrition, physical activity, stress management, and health responsibility. The researcher will measure height, weight, waist size, and blood pressure. Each student's diabetes risk will be scored using the Arabic version of the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK), which classifies risk as low, moderate, or high.

These data will be used to build a machine learning model that predicts each student's diabetes risk level from lifestyle and body measurement factors, and shows which factors influenced the prediction most. Students will then try the model and rate how useful and easy to use it is.

No treatment or intervention will be given. The study aims to support early identification of students at risk and to provide a model that nursing education programs and community health nurses could use in preventive health efforts.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Alexandria, Egypt, 21511
        • Faculty of Nursing, Alexandria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Third- and fourth-year (senior) undergraduate nursing students, male and female, enrolled at the Faculty of Nursing, Alexandria University, Egypt, who do not have diabetes or endocrine disorders affecting glucose metabolism and are not pregnant.

Description

Inclusion Criteria:

  • Regularly enrolled third- or fourth-year (senior) undergraduate nursing students at the Faculty of Nursing, Alexandria University.
  • Willing to provide written informed consent and participate voluntarily.
  • Have access to an internet-enabled electronic device (smartphone, tablet, or computer) and basic digital literacy.

Exclusion Criteria:

  • Previously diagnosed with type 1 or type 2 diabetes mellitus.
  • Chronic endocrine disorders known to affect glucose metabolism.
  • Pregnancy.
  • Incomplete or invalid questionnaire responses.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Senior Nursing Students

Description: Stratified random sample of third- and fourth-year (senior) nursing students at the Faculty of Nursing, Alexandria University, who complete the questionnaires and anthropometric measurements, contribute data for developing the AI model, and then try the model and rate its usefulness and ease of use.

A machine learning model developed from students' lifestyle (HPLP-II), anthropometric, and blood pressure data to predict type 2 diabetes risk level (low, moderate, high) and identify the most influential factors. Students will use the model once and rate its usefulness and ease of use. No treatment or lifestyle intervention is delivered

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Type 2 Diabetes Risk Level According to AUSDRISK
Time Frame: aseline (single assessment at data collection, up to 1 day per participant)

Proportion of senior nursing students classified as low risk (total score 4 or less), moderate risk (5 to 10), or high risk (11 or more) for developing type 2 diabetes, using the Arabic version of the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK). Total score ranges from 0 to 34; higher scores indicate higher risk.

aseline (single assessment at data collection, up to 1 day per participant)
Performance of the AI-Based Diabetes Risk Prediction Model
Time Frame: Upon completion of data collection and model development (up to 6 months after study start)

Accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of the machine learning model in classifying students into low, moderate, or high AUSDRISK risk categories, assessed on a held-out test set.

Upon completion of data collection and model development (up to 6 months after study start)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health-Promoting Lifestyle Profile II (HPLP-II) Score
Time Frame: Baseline (single assessment at data collection)

Total and subscale scores (health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, stress management) of the 52-item Arabic HPLP-II, rated on a 4-point scale (1 = never to 4 = routinely). Higher scores indicate more frequent health-promoting behaviors.

Baseline (single assessment at data collection)
Perceived Usefulness and Ease of Use of the AI Model
Time Frame: Immediately after the student uses the AI model (single assessment)

Scores on a 12-item questionnaire (6 items on perceived usefulness, 6 on perceived ease of use) rated on a 7-point scale (1 = strongly disagree to 7 = strongly agree). Higher scores indicate better perceived usefulness and ease of use.

Immediately after the student uses the AI model (single assessment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Dr. Mohamed Fakhry Ahmed Salem, Alexandria University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

October 30, 2026

First Submitted That Met QC Criteria

October 30, 2026

First Posted (Actual)

November 4, 2026

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

October 30, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • AU-20-6-242

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.